JUNSHI BIO (01877) subsidiary signs Distribution and Commercialization Agreement with LEO Pharma A/S

JUNSHI BIO (01877) announces that its wholly owned subsidiary TopAlliance Biosciences Inc. (hereinafter referred to as "Top Alliance") has signed a Distribution and Commercialization Agreement with LEO Pharma A/S (hereinafter referred to as "LEO Pharma"). According to the agreement, Top Alliance will grant LEO Pharma the exclusive rights to store, distribute, promote, market, and sell the product Tropifin monoclonal antibody in the European Union (EU) and European Economic Area (EEA) member states, as well as any future member states, Switzerland, and the United Kingdom (hereinafter referred to as the "Collaboration Region"). The announcement states that this cooperation is an important practice of the company's internationalization strategy of "rooted in China and layout globally," and a significant step for Top Alliance in expanding its business in the European market. The company will work together with partner LEO Pharma to actively prepare for the commercialization of Tropifin monoclonal antibody in the European region, leveraging LEO Pharma's mature drug distribution network and rich market promotion experience in the European market to accurately and efficiently cover patients in the Collaboration Region, significantly shorten the market introduction period, and provide high-quality treatment options for patients in the European region. This transaction will also enhance the product and company's brand influence globally and further expand the layout of the company's global commercialization network. This transaction is expected to have a positive impact on the company's continued operations.